Baidu
map

默克(Merck)、IAVI和印度血清研究所合作开发COVID-19单克隆抗体

2020-10-24 Allan MedSci原创

德国制药公司默克(Merck KGaA)、非营利性科研组织IAVI和印度血清研究所合作开发了针对COVID-19的单克隆抗体(mAb)。

德国制药公司默克(Merck KGaA)、非营利性科研组织IAVI和印度血清研究所合作开发了针对COVID-19的单克隆抗体(mAb)。

非营利性科研组织IAVI的科学家负责从COVID-19患者的血液中鉴定出单克隆抗体。如果发现与合作伙伴共同开发的mAb在临床试验中是有效的,无论是作为单一抗体还是两种候选药物的潜在组合,Merck KGaA都将实现这些药物在发达国家的商业化,印度血清研究所将实现包括印度在内的中低收入国家的商业化。

根据IAVI与默克(Merck KGaA)和印度血清研究所的协议,将进行一项加速的临床前和临床研究计划,以评估用于治疗COVID-19的抗体。预计I期临床试验将于2021年初开始。

IAVI总裁兼首席执行官Mark Feinberg表示:“我们敏锐地意识到单克隆抗体治疗COVID-19的巨大潜力。我们希望这种合作关系将为全球患者提供单克隆抗体”。

 

原始出处:

http://www.pharmatimes.com/news/merck_kgaa,_iavi_and_serum_institute_link_up_to_develop_covid-19_mabs_1354671

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1660234, encodeId=6fcc16602345f, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Tue Jul 06 21:50:01 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801073, encodeId=883718010e3f1, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Sun May 30 12:50:01 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661835, encodeId=f0ae166183532, content=<a href='/topic/show?id=2ba6115581e' target=_blank style='color:#2F92EE;'>#Merck#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11558, encryptionId=2ba6115581e, topicName=Merck)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=845e25340050, createdName=1249859em46(暂无昵称), createdTime=Sat May 01 21:50:01 CST 2021, time=2021-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273952, encodeId=c8af12e395250, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Mon Oct 26 10:50:01 CST 2020, time=2020-10-26, status=1, ipAttribution=)]
    2021-07-06 aids221
  2. [GetPortalCommentsPageByObjectIdResponse(id=1660234, encodeId=6fcc16602345f, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Tue Jul 06 21:50:01 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801073, encodeId=883718010e3f1, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Sun May 30 12:50:01 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661835, encodeId=f0ae166183532, content=<a href='/topic/show?id=2ba6115581e' target=_blank style='color:#2F92EE;'>#Merck#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11558, encryptionId=2ba6115581e, topicName=Merck)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=845e25340050, createdName=1249859em46(暂无昵称), createdTime=Sat May 01 21:50:01 CST 2021, time=2021-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273952, encodeId=c8af12e395250, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Mon Oct 26 10:50:01 CST 2020, time=2020-10-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1660234, encodeId=6fcc16602345f, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Tue Jul 06 21:50:01 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801073, encodeId=883718010e3f1, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Sun May 30 12:50:01 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661835, encodeId=f0ae166183532, content=<a href='/topic/show?id=2ba6115581e' target=_blank style='color:#2F92EE;'>#Merck#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11558, encryptionId=2ba6115581e, topicName=Merck)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=845e25340050, createdName=1249859em46(暂无昵称), createdTime=Sat May 01 21:50:01 CST 2021, time=2021-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273952, encodeId=c8af12e395250, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Mon Oct 26 10:50:01 CST 2020, time=2020-10-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1660234, encodeId=6fcc16602345f, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Tue Jul 06 21:50:01 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801073, encodeId=883718010e3f1, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Sun May 30 12:50:01 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661835, encodeId=f0ae166183532, content=<a href='/topic/show?id=2ba6115581e' target=_blank style='color:#2F92EE;'>#Merck#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11558, encryptionId=2ba6115581e, topicName=Merck)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=845e25340050, createdName=1249859em46(暂无昵称), createdTime=Sat May 01 21:50:01 CST 2021, time=2021-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273952, encodeId=c8af12e395250, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Mon Oct 26 10:50:01 CST 2020, time=2020-10-26, status=1, ipAttribution=)]

相关资讯

抗COVID-19单克隆抗体候选药物CT-P59:I期临床试验获得积极结果

制药公司Celltrion近日公布了CT-P59(抗COVID-19单克隆抗体候选药物)的I期临床试验的中期结果,结果显示,CT-P59具有良好的安全性、耐受性和药代动力学。

新型单克隆抗体治疗黄热病:安全有效

一项在《新英格兰医学杂志》(NEJM)的研究展示单克隆抗体TY014治疗黄热病(YF)的安全性和有效性。

君实生物重组全人源抗SARS-CoV-2单克隆抗体注射液进展良好

君实生物公布其重组全人源抗SARS-CoV-2单克隆抗体注射液联合疗法的进展,在降低病毒载量、减轻症状及降低和冠状病毒相关的住院及急诊治疗方面均显示出良好疗效。

张会来教授:PD-1/PD-L1单克隆抗体在恶性淋巴瘤的研究方向与热点问题

免疫检查点已成为当今肿瘤治疗最热门的领域之一,PD-1/ PD-L1作为免疫检查点最重要代表,目前已有6个抗体成功获得美国FDA 批准,包括三个PD-1抗体Nivolumab、Pembrolizumab、Cemiplimab,三个PD-L1抗体Atezolizumab、Avelumab、Durvalumab。我国NMPA也批准5个抗体,包括Nivolumab、Pembrolizumab、特瑞普利单

Science:CD20单克隆抗体治疗B细胞恶性肿瘤的奥秘

2020年8月14日,《Science》上发表了一篇论文,揭示了CD20治疗性抗体的差异结合机制。

Nat Commun:抗GARP:TGF-β1单抗能克服PD-1/PD-L1抑制剂耐药性

调节性T细胞(Treg)的免疫抑制作用对于外周免疫耐受的维持是不可或缺的,在癌症或慢性感染中该作用具有有害性。因此,在癌症患者中靶向Treg细胞及其功能的治疗策略的研究显得尤为重要。

拓展阅读

Critical Care Medicine:气道压力释放通气模式在COVID-19导致急性呼吸 衰竭的患者中的应用:一项单中心随机对照试验

与小潮气量机械通气相比,APRV通气模式并未缩短重症新冠肺炎机械通气患者的机械通气时间,也未改善患者的其他临床结局。

Radiology:超极化氙气MRI显示长期COVID患者的肺部异常

胸部X线片(CXR)是诊断急性COVID-19肺炎最常用的成像方式,对于需要入院治疗的患者,通常会在急性感染三个月后重复检查。

Radiology:基于胸部CT的COVID-19肺炎后1年的预后评估

胸部CT对疾病监测至关重要,时间是充分评估肺部恢复能力的关键因素。

Am J Resp Crit Care:半乳糖凝集素-3抑制剂治疗COVID-19肺炎

在COVID-19肺炎中,吸入GB013治疗的耐受性良好,达到了临床相关的血浆浓度。该研究的数据支持更大规模的临床试验来明确GB013的临床疗效。

European Radiology:如何实现影像学的标准COVID-19全自动预测?

放射组学是一种利用数学算法量化医学成像中病变的表型特征的方法,可用于预测疾病的严重程度和进展。

Lenzilumab 治疗 COVID-19 住院患者,未达到主要终点

FDA 已经拒绝了该公司寻求紧急使用该疗法治疗新住院 COVID-19 患者的请求。美国监管机构确定,它无法得出 lenzilumab 的潜在益处超过潜在风险的结论。

Baidu
map
Baidu
map
Baidu
map